Search | Clinical Trials Finder

Conditions: Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions: Estradiol, placebo; Drug
Lead sponsor: TherapeuticsMD; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Bacterial Vaginosis
Interventions: Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel; Drug
Lead sponsor: Starpharma Pty Ltd; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Phoenix, Arizona • San Diego, California • Metairie, Louisiana + 1 more

Conditions: Dyspareunia
Interventions: Estradiol, Imvexxy, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 1,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 42
States / cities: Birmingham, Alabama • Chandler, Arizona • Sacramento, California + 36 more

Conditions: Recurrent Bacterial Vaginosis
Interventions: Vaginal microbiome transplant, Oral Metronidazole, Sterile saline; Biological · Drug · Other
Lead sponsor: Douglas Kwon; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Labor, Premature
Interventions: Vaginal progesterone gel, Placebo vaginal gel; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Safety, Acceptability
Interventions: Placebo Intravaginal Ring A, Placebo Intravaginal Ring B; Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pelvic Organ Prolapse
Interventions: Solifenacin, Placebo, Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex; Drug · Device
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: High Risk MSM, HIV Negative, 18-30 Years of Age
Interventions: HEC Placebo Gel, Tenofovir 1% Gel; Other · Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Pregnancy
Interventions: 8% progesterone vaginal gel, Placebo Vaginal Gel; Drug
Lead sponsor: Juniper Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 636 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 45
States / cities: Mobile, Alabama • Tucson, Arizona • Colton, California + 39 more

Conditions: Pelvic Floor Disorders, Pelvic Pain
Interventions: Diazepam, Placebo; Drug
Lead sponsor: Raymond Foster; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: HIV Prevention
Interventions: Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel, Universal HEC Placebo Gel Formulation; Drug
Lead sponsor: Ian McGowan; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Los Angeles, California • Pittsburgh, Pennsylvania

Conditions: Vaginal Atrophy
Interventions: Placebo, DHEA (0.25%), DHEA (0.5%), DHEA (1.0%); Drug
Lead sponsor: EndoCeutics Inc.; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Cleveland, Ohio • Norfolk, Virginia

Conditions: Overactive Bladder
Interventions: DR-3001, Placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 81
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more

Conditions: Atrophic Vaginitis Due to Menopause
Interventions: Estradiol Vaginal Tablets 10 mcg, placebo; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 25
States / cities: Huntsville, Alabama • Montgomery, Alabama • San Diego, California + 19 more

Conditions: HIV
Interventions: Tenofovir (TFV) Alone Vaginal Tablet, Emtricitabine (FTC) Alone Vaginal Tablet, TFV and FTC Combined Vaginal Tablet, Placebo Vaginal Tablet; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: The Bronx, New York • Norfolk, Virginia

Conditions: HIV
Interventions: TDF Intravaginal Ring, Placebo Intravaginal Ring; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Prevention
Interventions: Tenofovir 1% vaginal gel, Depo-medroxyprogesterone acetate (DMPA), Oral contraceptive: LNG 150 mcg and EE 30 mcg; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Norfolk, Virginia

Conditions: Postmenopausal Symptoms
Interventions: Estrogel, Placebo; Drug · Other
Lead sponsor: ASCEND Therapeutics; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 109
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more

Conditions: Atrophic Vaginitis
Interventions: Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream, Placebo Vaginal Cream; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 366 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 21
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more

Conditions: Vaginitis Gardnerella
Interventions: Amoxicillin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • Winston-Salem, North Carolina

Conditions: Bacterial Vaginosis
Interventions: Lactobacillus crispatus CTV-05, Metronidazole, Placebo; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: San Diego, California • San Francisco, California • Chicago, Illinois + 1 more

Conditions: HIV Infections
Interventions: Dapivirine Vaginal Ring, Maraviroc Vaginal Ring, Placebo Vaginal Ring, Dapivirine-Maraviroc Vaginal Ring; Drug · Other
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Hypoactive Sexual Desire Disorder (HSDD)
Interventions: Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert; Drug
Lead sponsor: EndoCeutics Inc.; Industry
Eligibility: 40 Years to 80 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 10
States / cities: Huntsville, Alabama • San Diego, California • New London, Connecticut + 7 more

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert; Drug
Lead sponsor: EndoCeutics Inc.; Industry
Eligibility: 40 Years to 80 Years · Female only
Enrollment: 653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 63
States / cities: Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 53 more

Search by objective public record fields.

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy

Vaginal Microbiota Transplant

Vaginal Progesterone as a Treatment for Women Active Preterm Labor

Trial to Assess Acceptability and Safety of Two Placebo Intravaginal Rings

Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse

Microbicide Safety and Acceptability in Young Men

Vaginal Progesterone to Reduce the Risk of Another Preterm Birth

Vaginal Diazepam for the Treatment of Female Pelvic Pain

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

Topical DHEA Against Vaginal Atrophy

A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder

Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo

Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine

Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis

Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin

LACTIN-V Study for Recurrent Bacterial Vaginosis

Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)